Bronchodilator reversibility testing in chronic obstructive pulmonary disease
PMA Calverley, PS Burge, S Spencer, JA Anderson… - Thorax, 2003 - thorax.bmj.com
Background: A limited or absent bronchodilator response is used to classify chronic
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
[HTML][HTML] Comorbid conditions in chronic obstructive pulmonary disease: Potential therapeutic targets for unmet needs
K Matsunaga, M Harada, J Suizu, K Oishi… - Journal of Clinical …, 2020 - mdpi.com
The management of chronic obstructive pulmonary disease (COPD) has improved
significantly due to advances in therapeutic agents, but it has also become apparent that …
significantly due to advances in therapeutic agents, but it has also become apparent that …
COPD phenotypes according to high resolution CT scan findings
A Shah, U Shah, TK Jayalakshmi… - European …, 2014 - Eur Respiratory Soc
[BACKGROUND] High Resolution Computed Tomography Scan (HRCT) is now being used
as an important diagnostic test in COPD patients. In present study, we have evaluated …
as an important diagnostic test in COPD patients. In present study, we have evaluated …
Chronic obstructive pulmonary disease (COPD) and COPD-like phenotypes
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. Historically,
two COPD phenotypes have been described: chronic bronchitis and emphysema. Although …
two COPD phenotypes have been described: chronic bronchitis and emphysema. Although …
Biomarkers in chronic obstructive pulmonary disease
Currently, with exception of lung function tests, there are no well validated biomarkers or
surrogate endpoints that can be used to establish efficacy of novel drugs for chronic …
surrogate endpoints that can be used to establish efficacy of novel drugs for chronic …
Chronic bronchitic symptoms are associated with worse symptoms and greater exacerbation frequency in COPD
Methods: The COPDGene® study enrolled non-hispanic white and African American
subjects with a smoking history of at least 10 pack-years. We included subjects with COPD …
subjects with a smoking history of at least 10 pack-years. We included subjects with COPD …
Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?
O Turan, N Ogan, F Bozkus, N Sarıoğlu… - European Journal of …, 2024 - Springer
Methods The study cohort was formed of all subjects from six pulmonology clinics with an
initial diagnosis of COPD who were new users of a LAMA or LABA from January 2020 to …
initial diagnosis of COPD who were new users of a LAMA or LABA from January 2020 to …
A prospective cohort study to assess obstructive respiratory disease phenotypes and endotypes in Japan: the TRAIT study design
N Hizawa, K Fukunaga, H Sugiura… - … Journal of Chronic …, 2021 - Taylor & Francis
Background Asthma, chronic obstructive pulmonary disease (COPD), and asthma–COPD
overlap (ACO) are complex and heterogeneous diseases that share clinical characteristics …
overlap (ACO) are complex and heterogeneous diseases that share clinical characteristics …
Personalized medicine and chronic obstructive pulmonary disease
EFM Wouters, B Wouters, IML Augustin… - Current opinion in …, 2017 - journals.lww.com
Personalized medicine and chronic obstructive pulmonary dise... : Current Opinion in
Pulmonary Medicine Personalized medicine and chronic obstructive pulmonary disease …
Pulmonary Medicine Personalized medicine and chronic obstructive pulmonary disease …
COPD: CardiOPulmonary disease?
SM Kawut - European Respiratory Journal, 2013 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is defined by the presence of airflow
limitation which is not fully reversible, but COPD encompasses numerous phenotypes [ 1] …
limitation which is not fully reversible, but COPD encompasses numerous phenotypes [ 1] …